Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for HRS-7058, an innovative and selective drug candidate, in patients with advanced solid tumors harboring the KRAS G12C mutation. This development marks a significant step for Hengrui Medicine as HRS-7058 aims to address a therapeutic gap in China, where no similar product has yet been approved for the treatment of KRAS G12C mutant solid tumors.
While Amgen’s sotorasib is available in international markets, several other competitors are advancing in the Chinese pharmaceutical landscape. These include Innovent’s GFH925, Jemincare’s JMKX001899, InventisBio’s garsorasib, which has already filed for marketing, and Jacobio’s glecirasib, all of which are under development within the country.- Flcube.com
